Johnson & Johnson (NYSE:JNJ) Shares Sold by Israel Discount Bank of New York

Israel Discount Bank of New York cut its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 6.1% in the 1st quarter, Holdings Channel.com reports. The firm owned 4,301 shares of the company’s stock after selling 280 shares during the period. Israel Discount Bank of New York’s holdings in Johnson & Johnson were worth $762,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently bought and sold shares of the stock. Ulland Investment Advisors LLC purchased a new position in Johnson & Johnson during the 4th quarter worth $296,000. Castle Rock Wealth Management LLC increased its stake in shares of Johnson & Johnson by 3.9% during the fourth quarter. Castle Rock Wealth Management LLC now owns 12,855 shares of the company’s stock worth $2,119,000 after acquiring an additional 479 shares during the period. Rehmann Capital Advisory Group increased its stake in shares of Johnson & Johnson by 3.2% during the fourth quarter. Rehmann Capital Advisory Group now owns 43,045 shares of the company’s stock worth $7,364,000 after acquiring an additional 1,348 shares during the period. Lynch Asset Management Inc. acquired a new position in shares of Johnson & Johnson during the fourth quarter worth about $1,625,000. Finally, Richwood Investment Advisors LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter worth about $664,000. Hedge funds and other institutional investors own 68.78% of the company’s stock.

A number of research analysts have recently issued reports on JNJ shares. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 17th. Morgan Stanley dropped their price target on shares of Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 6th. Sanford C. Bernstein lowered shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and boosted their price target for the stock from $180.00 to $183.00 in a research note on Wednesday, March 16th. Credit Suisse Group upped their target price on shares of Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. Finally, Daiwa Capital Markets assumed coverage on shares of Johnson & Johnson in a research report on Wednesday. They set an “outperform” rating on the stock. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $190.50.

In other news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares in the company, valued at $12,336,803. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider William Hait sold 29,699 shares of the company’s stock in a transaction that occurred on Thursday, April 21st. The shares were sold at an average price of $183.58, for a total transaction of $5,452,142.42. Following the transaction, the insider now directly owns 80,236 shares in the company, valued at approximately $14,729,724.88. The disclosure for this sale can be found here. In the last quarter, insiders have sold 78,161 shares of company stock valued at $13,895,302. 0.35% of the stock is currently owned by company insiders.

Shares of JNJ opened at $175.74 on Thursday. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The stock has a market cap of $462.44 billion, a P/E ratio of 23.68, a PEG ratio of 3.35 and a beta of 0.66. The company has a current ratio of 1.39, a quick ratio of 1.14 and a debt-to-equity ratio of 0.39. The company has a 50-day moving average of $177.66 and a two-hundred day moving average of $173.09.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings data on Tuesday, April 19th. The company reported $2.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.60 by $0.07. The firm had revenue of $23.43 billion during the quarter, compared to the consensus estimate of $23.62 billion. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The company’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.59 EPS. As a group, analysts forecast that Johnson & Johnson will post 10.23 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 7th. Investors of record on Tuesday, May 24th were paid a dividend of $1.13 per share. The ex-dividend date of this dividend was Monday, May 23rd. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.57%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.06. Johnson & Johnson’s dividend payout ratio (DPR) is presently 60.92%.

Johnson & Johnson Company Profile (Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.